Objective: The correlation between serum ApoC III and galectin-3 levels and adverse maternal and infant outcomes in GDM patients was analyzed.
Methods: A total of 97 GDM patients admitted to our hospital from January 2019 to June 2021 were selected and divided into a good group and a poor group according to the pregnancy outcomes, ApoC III in blood of subjects was detected by immunoturbidimetry, and galectin-3 level was detected by enzyme-linked immunosorbent assay. Spearman correlation test was used to analyze the correlation between ApoC III and galectin-3 levels and pregnancy outcomes in patients with GDM, and ROC curves were drawn to analyze the value of each index alone and in combination to predict pregnancy outcomes in patients with GDM.
Results: The levels of ApoC III and galectin-3 in the blood of the patients in the bad group were significantly higher than those in the good group, and the difference was statistically significant ( = 11.231, 14.965, < 0.05). The levels of ApoC III and galectin-3 in the blood of GDM patients were significantly positively correlated with adverse pregnancy outcomes, and there was a statistical significance ( = 0.754 and = 0.698, < 0.05). The combined application of ApoC III and galectin-3 levels in GDM patients' blood to predict the adverse outcome of pregnancy was Log = 0.623, ApoC III+0.605 galectin-3. The sensitivity, specificity, and AUC of combined application of ApoC III and galectin-3 for predicting adverse pregnancy outcomes in GDM patients were all greater than 90%, and AUC>0.90. The combined application in predicting adverse pregnancy outcomes were higher than those of the individual indicators, and the difference was statistically significant ( < 0.05).
Conclusion: The levels of ApoC III and galectin-3 in the blood of GDM patients with adverse pregnancy outcomes were significantly increased, and the detection of ApoC III and galectin-3 could effectively improve the value of predicting adverse pregnancy in GDM.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9553661 | PMC |
| http://dx.doi.org/10.1155/2022/5089529 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study.
Medicine (Baltimore)
December 2024
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Dyslipidemia has been established as a potential risk factor for venous thromboembolism (VTE) in several observational studies. Statins and novel lipid-modifying agents are being explored for their potential in VTE prevention, encompassing deep vein thrombosis (DVT), and pulmonary embolism (PE). Nonetheless, conclusive evidence supporting the effectiveness remains uncertain.
View Article and Find Full Text PDFMultifaceted Role of Apolipoprotein C3 in Cardiovascular Disease Risk and Metabolic Disorder in Diabetes.
Int J Mol Sci
November 2024
Graduate Institute of Biomedical Sciences, China Medical University, Taichung 40402, Taiwan.
Apolipoprotein C3 (APOC3) plays a critical role in regulating triglyceride levels and serves as a key predictor of cardiovascular disease (CVD) risk, particularly in patients with diabetes. While APOC3 is known to inhibit lipoprotein lipase, recent findings reveal its broader influence across lipoprotein metabolism, where it modulates the structure and function of various lipoproteins. Therefore, this review examines the complex metabolic cycle of APOC3, emphasizing the impact of APOC3-containing lipoproteins on human metabolism, particularly in patients with diabetes.
View Article and Find Full Text PDFNovel agents for treating severe hypertriglyceridemia.
Med
December 2024
Department of Metabolic Medicine/Chemical Pathology, Guy's & St Thomas' Hospitals, London, UK. Electronic address:
The PALISADE trial extended the data available for inhibition of apolipoprotein (apo) C3 inhibition for treating severe hypertriglyceridemia. 75 patients with persistent chylomicronemia were allocated to 2 doses of plozasiran or placebo. Triglycerides were reduced by a net 53%-58%, and a borderline significant 17% reduction was seen in pancreatitis events.
View Article and Find Full Text PDFMetabolic Dysfunction-Associated Steatotic Liver Disease, Hypertriglyceridemia and Cardiovascular Risk.
Eur J Prev Cardiol
December 2024
Metabolism and Lipids Program, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver conditions ranging from simple steatosis to the more severe metabolic dysfunction-associated steatohepatitis (MASH). MASLD is strongly linked to insulin resistance disorders, with a high prevalence among patients with type 2 diabetes. Long-term complications include liver cirrhosis, liver cancer, and cardiovascular disease.
View Article and Find Full Text PDFFamilial chylomicronemia: New perspectives.
Clin Investig Arterioscler
December 2024
Unidad de Lípidos y Riesgo Cardiovascular, Servicio de Medicina Interna, Complejo Hospitalario Universitario de A Coruña, A Coruña, España. Electronic address:
Familial chylomicronemia syndrome (FCS) is a very rare, underdiagnosed disorder that can cause abdominal pain and recurrent pancreatitis from childhood -potentially life-threatening- and chronic complications such as diabetes mellitus and exocrine pancreatic insufficiency. FCS affects the quality of life and mental health of those who suffer from it, aspects that must be taken into account in its treatment, based on a strict low-fat diet, which is difficult to adhere to and persist. People with FCS lack the lipolytic capacity to hydrolyze triglycerides (TG) and have a minimal or null response to conventional lipid-lowering treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!